SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

Home・Akcijų sąrašas・Pharma Mar SA

P
Pharma Mar SA

Atidarymo kaina

98.9 5.89

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

92.15

Max

99.5

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-58M 1.6M
Pardavimai	-48M 43M
P/E Sektoriaus vid.	21.191 49.888
Pelnas, tenkantis vienai akcijai	0.088
Pelno marža	3.725
Darbuotojai	505
EBITDA	-40M 2.7M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+27.25% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	40M 1.7B
Ankstesnė atidarymo kaina	93.01
Ankstesnė uždarymo kaina	98.9

Pharma Mar SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-04 21:51; UTC

Pagrindinės rinkos jėgos

Merlin Shares Rally After Defense Department's Design Review Wraps

2026-06-04 23:46; UTC

Rinkos pokalbiai

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026-06-04 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-06-04 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026-06-04 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia to Enter Trading Halt

2026-06-04 23:34; UTC

Rinkos pokalbiai

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-04 23:08; UTC

Rinkos pokalbiai

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026-06-04 22:41; UTC

Rinkos pokalbiai

Australia Shares Set to Rise at the Open -- Market Talk

2026-06-04 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 20:44; UTC

Įsigijimai, susijungimai, perėmimai

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026-06-04 20:16; UTC

Rinkos pokalbiai

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026-06-04 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026-06-04 19:46; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026-06-04 19:38; UTC

Rinkos pokalbiai

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026-06-04 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026-06-04 18:47; UTC

Įsigijimai, susijungimai, perėmimai

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026-06-04 18:38; UTC

Uždarbis

Money Quote: Tech Weakness in Context -- WSJ

2026-06-04 18:24; UTC

Uždarbis

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 17:09; UTC

Rinkos pokalbiai

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026-06-04 16:58; UTC

Uždarbis

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 16:46; UTC

Rinkos pokalbiai

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026-06-04 16:38; UTC

Uždarbis

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026-06-04 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-04 16:13; UTC

Rinkos pokalbiai

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026-06-04 16:11; UTC

Rinkos pokalbiai

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026-06-04 15:56; UTC

Rinkos pokalbiai

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Akcijų palyginimas

Kainos pokytis

Pharma Mar SA Prognozė

Kainos tikslas

By TipRanks

27.25% į viršų

12 mėnesių prognozė

Vidutinis 120.502 EUR 27.25%

Aukščiausias 121 EUR

Žemiausias 120 EUR

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pharma Mar SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Pharma Mar SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.